Irbesartan

Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease^[1]. In Vitro: Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro^[1].
Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro^[1].
Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro^[1]. In Vivo: Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice^[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects^[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II^[1].
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice^[1].